A quick analysis of Celgene Corporation(NASDAQ: CELG) stock history reveals three distinct stages with four stock splits along the way. These stages led to the company becoming what the following chart shows it to be -- one of the …
Celgene turned in a brutal third-quarter earnings report, missing revenue forecasts and cutting its long-term profit outlook. Traders were woefully unhedged by several measures, leaving them vulnerable to feel the brunt of the stock's 20% drop. …
Even some of the biggest and best have things go wrong every now and then. Celgene (NASDAQ: CELG) has been the best-performing biotech stock over the last five years among big biotechs with market caps over $50 billion. And now, …
Celgene (NASDAQ: CELG) stock has been in my investment portfolio since 2013. I enjoyed a couple of great years with the biotech stock performing really well. Over the past couple of years, however, Celgene hasn't generated high …
Celgene Corp. (NASDAQ: CELG) has decided to join the stock split game. Stock splits do not create any fundamental change on the surface, but the problem that Celgene has faced is that the run up in shares has lowered its average …
a wholly-owned subsidiary of Celgene (“Purchaser”), and Juno Therapeutics, Inc. (“Juno”). to the Merger Agreement, Purchaser will commence a tender offer to purchase all of the issued and outstanding shares of Juno s common stock, …
This article is the second in a two-part series on applying the principles of value investing. In part 1 found here my primary focus was on the benefits of investing in fundamentally strong dividend growth stocks when they are out of favor, and …
SmarTrend identified a Downtrend for Celgene Corp (NASDAQ:CELG) on October 13th, 2017 at $137.01. In approximately 2 months, Celgene Corp has returned 22.39% as of today's recent price of $106.33. In the past 52 weeks, shares of …